samedan logo

home > ebr > summer 2013 > insider information
European Biopharmaceutical Review

Insider Information

EBR: What was your entry point into the pharmaceutical industry?

JW: Bristol-Myers Squibb (then Bristol-Myers) was a client when I was a partner in a mid-size New York public relations agency. A few years into the relationship I joined the corporate public affairs department reporting to the chairman’s office. For the next 16 years, I engaged across the entire organisation, supporting most of the business units in product support, global M&A activities and issues, and crisis management. I was able to take early retirement in 2000, which is when I formed Weisberg Communications Company.

Which part of your current role do you most enjoy? Applying my knowledge to help organisations become better understood is quite satisfying. Most rewarding is participating in the global development of the SAFE-BioPharma digital identity and signature standard. It is an industry-supported initiative that facilitates greater collaboration through the use of trusted cyber identities for authenticating users and for applying digital signatures to electronic documents. Currently it’s used primarily in R&D.

Which part is the most challenging? Managing the tsunami of irrelevant and inaccurate information has become a social disease. The upside is that it creates opportunity for those who establish and maintain credibility through useful and valid information.

How would you describe your business philosophy? In terms of my PR speciality, I believe that good PR is based on good policy. That means it’s important to either be at the table or have the ear of someone who is. In more general terms, I believe in understanding the business landscape and navigating it with strong skills and common sense. I always ask questions.

What motivates you? I’m motivated by having a clear understanding of strategic goals, peer review, and the personal satisfaction that comes with strong, professional performance.

What has been your proudest moment? Two stand out from my Bristol- Myers Squibb years. Firstly, the campaign I implemented to get the Japanese government to establish a fair reimbursement price for Taxol, the ovarian cancer treatment, and secondly being one of the creator/developers of Secure The Future, the AIDS relief programme for women and children in five southern African countries. More recently, I’m proud of the impact SAFE-BioPharma is having on the biopharmaceutical industry.

And your greatest disappointment? Not having ski-bummed for a few seasons after graduate school. Living a short drive from some of the world’s best powder skiing is making up for that now.

What does the pharma sector need to focus on in 2013? The pipeline is lacking and the pressure is mounting. It’s time for a different approach to cost-cutting. Let’s invest more in information technologies that will improve cost efficiencies and get us positioned for a more collaborative future.

How do you think the pharmaceutical industry as a whole will change over the next 10 years? Significant changes are occurring in how we learn and how we understand the human organism. Over the coming decade, those forces will continue to develop and merge with powerful therapeutic results. I hope they’ll raise the bar beyond dealing with our current economic and political pressures.

What is the most important lesson you have learnt? Add value to everything you do.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Jon Weisberg is President of Weisberg Communications Company. He also heads public relations and communications for the industry consortium, SAFE-BioPharma Association. For 16 years, Jon was a senior public relations executive on the corporate staff of Bristol-Myers Squibb Company.
Jon Weisberg
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gerresheimer opens a new plant for the production of pharmaceutical primary plastic packaging in China

Düsseldorf/Changzhou, December 11, 2019 – A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. Today the new facility will be officially opened.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement